BioOutsource to Open New Massachusetts Lab Facility

FDA Extends Review Period for GSK’s Blenrep

The biological reagents provider is moving to a 5000-square-foot site in Cambridge Technopark to accommodate the company’s growth.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

CGT Catapult Invests in Spliceor Trans-Splicing Gene Therapy Platform

The agency has extended the review period for GSK’s biologics license application for belantamab mafodotin-blmf for the treatment of relapsed/refractory multiple myeloma.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Grants Regenerative Medicine Advanced Therapy Designation to Gene Therapy for Knee OA

The investment is part of CGT Catapult’s Cross-Catapult Investment Pilot and will accelerate the pre-clinical development of Spliceor’s trans-splicing gene therapy platform.

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | Image Credit: © Tada Images - stock.adobe.com

AATec Medical and Northway Biotech Partner to Develop Lung Disease Therapy

Genascence’s first-in-class gene therapy blocking interleukin 1, GNSC-001, will enter a Phase IIb/III study in 2026.

MIT Researchers Identify Compounds that Fight Viral Infections

Northway Biotech will develop and scale production of AATec’s ATL-105 for the treatment of non-CF bronchiectasis.

Antibodies.com Moves to Expanded UK Headquarters

Scientists at MIT and other institutions have discovered compounds that activate a defense pathway inside host cells that could be used as antiviral drugs.

Related Content

FDA Extends Review Period for GSK’s Blenrep

The biological reagents provider is moving to a 5000-square-foot site in Cambridge Technopark to accommodate the company’s growth.

CGT Catapult Invests in Spliceor Trans-Splicing Gene Therapy Platform

The agency has extended the review period for GSK’s biologics license application for belantamab mafodotin-blmf for the treatment of relapsed/refractory multiple myeloma.

FDA Grants Regenerative Medicine Advanced Therapy Designation to Gene Therapy for Knee OA

The investment is part of CGT Catapult’s Cross-Catapult Investment Pilot and will accelerate the pre-clinical development of Spliceor’s trans-splicing gene therapy platform.

AATec Medical and Northway Biotech Partner to Develop Lung Disease Therapy

Genascence’s first-in-class gene therapy blocking interleukin 1, GNSC-001, will enter a Phase IIb/III study in 2026.

MIT Researchers Identify Compounds that Fight Viral Infections

Northway Biotech will develop and scale production of AATec’s ATL-105 for the treatment of non-CF bronchiectasis.